Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
Panelists discuss how recent clinical trials have demonstrated improved outcomes with antibody-containing regimens and biomarker-driven approaches in patients with transplant not-preferred newly diagnosed multiple myeloma (NDMM).
EP: 1.Current Strategies for Frontline Therapy in Transplant-Preferred NDMM
EP: 2.Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
EP: 3.Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations
EP: 4.Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM
EP: 5.Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM
EP: 6.Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Video content above is prompted by the following:
- What are your perspectives on the data from the MAIA, BENEFIT, and IMROZ trials?
- How does the data impact frontline treatment for patients with NDMM who are not transplant-preferred?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
